Skip to main content About News Giving All Departments Contact Us Site Map
 University of Texas Southwestern Medical School
 
Search       
Print Friendly  
spacer Home Education Research Patient Care Faculty & Administration Resource Careers
Faculty Directory Administration Administrative Departments
border=0
| Home > Faculty & Administration >
Emmanouil Brilakis

 
 
Faculty Directory
 
 
Find a Doctor
 
 
Faculty Research Interests
 
 
Search Help
 
 
Update Faculty ProfileAccessible on campus or vpn
 
 
 

Emmanouil Brilakis, M.D., Ph.D.

 Details of Research

Biographical Sketch Details of Research Personal Overview How to Contact
Emmanouil Brilakis
Name:
  Emmanouil S Brilakis, M.D., Ph.D.
Academic Title:
  Assistant Professor
Primary Appointment:
  Internal Medicine - Cardiology
School:
  Southwestern Medical School
Affiliations:
  Cardiology
Email:
  Emmanouil Brilakis, M.D., Ph.D.

 RESEARCH OVERVIEW
 
The main focus of our research is on improving the outcomes of patients after coronary artery bypass graft surgery (CABG). Saphenous vein grafts (SVGs) are used in the majority of CABG operations but have high risk of failure. We are investigating all stages of SVG failure, early and late.

We recently reported and published the first multicenter trial of drug-eluting stents in SVGs, the SOS (Stenting Of Saphenous vein graft trial), that showed significant reduction of angiographic restenosis with use of drug-eluting stents. Through the VA Cooperative Studies Program we have been developing the largest stenting trial in saphenous vein grafts ever to be performed.
We recently showed that intensive low-density cholesterol lowering therapy may improve clinical outcomes in prior CABG patients, yet they still have high cardiovascular risk, and multiple poorly controlled atherosclerosis risk factors. We are developing a trial that will examine the role of extended-release niacin in moderate SVG lesions using intravascular ultrasonography.

The second major focus of our research is to determine the optimum antiplatelet therapy after coronary artery stenting. We recently showed that continuation of clopidogrel for more than 12 months in drug-eluting stent patients may be associated with lower mortality. We are currently evaluating the risk of surgery after drug-eluting stent implantation and the optimum perioperative medical management.

Finally, in collaboration with Drs Jian Yang and Panayotis Shiakolas at UT Arlington we are developing a novel bioresorbable stent that is currently undergoing animal testing.
 
 RESEARCH INTERESTS
 
Aortoconary saphenous vein bypass grafts: interventional and medical treatment
Perioperative management of coronary stents
Intravascular ultrasonography and coronary physiology
Development of new coronary stents
Evaluation of novel atherosclerosis risk factors
 
 RECENT PUBLICATIONS
 
Brilakis ES, Saeed, B, Banerjee S, "Use of Drug-Eluting Stents in Saphenous Vein Aortocoronary Bypass Graft Lesions: a Critical Appraisal" J Interv Cardiol, 21:151-157, 2008
Varghese I, Boatman DM, Peters CT, Daye J, Haider A, Roesle M, Banerjee S, Brilakis ES, "Impact on Contrast, Fluoroscopy, and Catheter Utilization From Knowing the Coronary Artery Bypass Graft Anatomy Before Diagnostic Coronary Angiography" Am J Cardiol, 101:1729-1732, 2008
Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E, "Outcomes of Patients With Acute Coronary Syndrome and Prior Coronary Artery Bypass Grafting. Results (From the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE-IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)" Am J Cardiol, 102:552-8, 2008
Brilakis ES, Khera A, Saeed, B, , Banerjee S , McGuire DK, Murphy SA, de Lemos JA, "Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Coronary and Aortic Atherosclerosis: Findings From the Dallas Heart Study." Clinical Chemistry, 54:1975-81, 2008
Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de Lemos JA, "Influence of Race and Sex on Lipoprotein-Associated Phospholipase A2 Levels: Observations from the Dallas Heart Study" Atherosclerosis, 199:110-115, 2008
 
 SIGNIFICANT PUBLICATIONS
 
Brilakis ES, Banerjee S, Berger PB., "Perioperative management of coronary stents" J Am Coll Cardiol, 49:2145-50, 2007
Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB, "Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease" N Engl J Med, 353:46-57, 2005
Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, "A Randomized-Controlled Trial Of A Paclitaxel-Eluting Stent vs. A Similar Bare Metal Stent In Saphenous Vein Graft Lesions. The SOS (Stenting Of Saphenous Vein Grafts) Trial" J Am Coll Cardiol, 53:919?28, 2009
 
Point and right click (click and hold for Mac users) your mouse on and select "Save this link (or target) as..." option to save the file to your local computer.